JP2022505928A5 - - Google Patents
Info
- Publication number
- JP2022505928A5 JP2022505928A5 JP2021523014A JP2021523014A JP2022505928A5 JP 2022505928 A5 JP2022505928 A5 JP 2022505928A5 JP 2021523014 A JP2021523014 A JP 2021523014A JP 2021523014 A JP2021523014 A JP 2021523014A JP 2022505928 A5 JP2022505928 A5 JP 2022505928A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- nanoparticles
- pharmaceutically acceptable
- acceptable salt
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862748798P | 2018-10-22 | 2018-10-22 | |
| US62/748,798 | 2018-10-22 | ||
| PCT/US2019/057406 WO2020086555A1 (en) | 2018-10-22 | 2019-10-22 | Antiviral prodrugs and nanoformulations thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022505928A JP2022505928A (ja) | 2022-01-14 |
| JP2022505928A5 true JP2022505928A5 (https=) | 2022-11-09 |
| JP7437051B2 JP7437051B2 (ja) | 2024-02-22 |
Family
ID=70331730
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021523014A Active JP7437051B2 (ja) | 2018-10-22 | 2019-10-22 | 抗ウイルスプロドラッグおよびそのナノ製剤 |
Country Status (18)
| Country | Link |
|---|---|
| US (5) | US11154557B2 (https=) |
| EP (3) | EP3870174B1 (https=) |
| JP (1) | JP7437051B2 (https=) |
| KR (2) | KR102856407B1 (https=) |
| CN (2) | CN116375735B (https=) |
| AU (2) | AU2019368247B2 (https=) |
| BR (1) | BR112021007622A2 (https=) |
| CA (1) | CA3117453A1 (https=) |
| EA (1) | EA202190974A1 (https=) |
| ES (2) | ES3062664T3 (https=) |
| IL (2) | IL320867A (https=) |
| MX (2) | MX2021004679A (https=) |
| MY (1) | MY207622A (https=) |
| PH (1) | PH12021550905A1 (https=) |
| SA (1) | SA521421845B1 (https=) |
| SG (1) | SG11202104117WA (https=) |
| WO (1) | WO2020086555A1 (https=) |
| ZA (2) | ZA202102846B (https=) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3870174B1 (en) | 2018-10-22 | 2023-11-01 | Board of Regents of the University of Nebraska | Antiviral prodrugs and nanoformulations thereof |
| CN120535538A (zh) | 2018-11-29 | 2025-08-26 | 内布拉斯加大学董事会 | 抗病毒前药及其纳米制剂 |
| MY201239A (en) | 2019-03-22 | 2024-02-13 | Gilead Sciences Inc | Bridged tricyclic carbamoylpyridone compounds and their pharmaceutical use |
| PE20221569A1 (es) | 2020-02-24 | 2022-10-06 | Gilead Sciences Inc | Compuestos tetraciclicos para el tratamiento de infecciones por vih |
| ES3064867T3 (en) | 2020-09-30 | 2026-04-29 | Gilead Sciences Inc | Bridged tricyclic carbamoylpyridone compounds for a use in the treatment of hiv |
| US11613546B2 (en) | 2021-01-19 | 2023-03-28 | Gilead Sciences, Inc. | Substituted pyridotriazine compounds and uses thereof |
| WO2023183472A1 (en) * | 2022-03-23 | 2023-09-28 | Board Of Regents Of The University Of Nebraska | Antiviral prodrugs and use thereof |
| TW202446773A (zh) | 2022-04-06 | 2024-12-01 | 美商基利科學股份有限公司 | 橋聯三環胺甲醯基吡啶酮化合物及其用途 |
| AU2024209826A1 (en) * | 2023-01-18 | 2025-07-10 | Ascletis BioScience Co., Ltd | Integrase inhibitor and use thereof |
| EP4680242A1 (en) * | 2023-03-17 | 2026-01-21 | Exavir Therapeutics, Inc. | Formulations of an antiviral prodrug |
| EP4680339A1 (en) * | 2023-03-17 | 2026-01-21 | Exavir Therapeutics, Inc. | Crystalline forms of an antiviral prodrug |
| WO2024227037A1 (en) * | 2023-04-26 | 2024-10-31 | University Of Washington | Long-acting colloidal pharmaceutical compositions of integrase strand transfer inhibitors and related methods |
| WO2025011661A1 (zh) * | 2023-07-12 | 2025-01-16 | 歌礼生物科技（杭州）有限公司 | 整合酶抑制类的制剂及其制备方法 |
| WO2025128496A1 (en) | 2023-12-12 | 2025-06-19 | Viiv Healthcare Company | Crystalline form |
| WO2025128498A1 (en) * | 2023-12-12 | 2025-06-19 | Viiv Healthcare Company | Pharmaceutical compositions |
| WO2026012272A1 (en) * | 2024-07-12 | 2026-01-15 | Ascletis Bioscience Co., Ltd. | Integrase inhibitor and use thereof |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101363875B1 (ko) * | 2005-04-28 | 2014-02-21 | 시오노기세야쿠 가부시키가이샤 | Ｈｉｖ 통합효소 억제 활성을 가지는 다환식카르바모일피리돈 유도체 |
| WO2010011814A1 (en) * | 2008-07-25 | 2010-01-28 | Smithkline Beecham Corporation | Chemical compounds |
| ES2608377T3 (es) * | 2010-08-05 | 2017-04-10 | Shionogi & Co., Ltd. | Procedimiento de preparación de un compuesto que tiene actividad inhibidora de la integrasa del HIV |
| TWI577377B (zh) * | 2010-09-16 | 2017-04-11 | Ｖｉｉｖ醫療保健公司 | 醫藥組合物 |
| DK2620436T3 (en) * | 2010-09-24 | 2018-07-30 | Shionogi & Co | Substituted polycyclic carbamoylpyridone derivative prodrug |
| MX2013004981A (es) | 2010-11-02 | 2013-11-04 | Univ Nebraska | Composiciones y metodos para la administracion de agentes terapeuticos. |
| WO2014047562A2 (en) * | 2012-09-21 | 2014-03-27 | Epiphany Biosciences | Method of treating and/or preventing shingles and method of treating and/or preventing zoster associated pain |
| CN104884059B (zh) | 2012-11-30 | 2018-08-10 | 罗切斯特大学 | 用于hiv/aids治疗的混合谱系激酶抑制剂 |
| EA030003B1 (ru) * | 2012-12-21 | 2018-06-29 | Джилид Сайэнс, Инк. | Полициклическое карбамоилпиридоновое соединение и его фармацевтическое применение для лечения вич-инфекции |
| PE20151063A1 (es) * | 2012-12-27 | 2015-08-03 | Japan Tobacco Inc | DERIVADO SUSTITUIDO DE ESPIROPIRIDO[1,2-a]PIRAZINA Y USO MEDICO DEL MISMO COMO INHIBIDOR DE LA INTEGRASA DEL VIH |
| EP3008044B1 (en) | 2013-06-13 | 2018-11-21 | Merck Sharp & Dohme Corp. | Fused tricyclic heterocyclic compounds as hiv integrase inhibitors |
| JP2016528240A (ja) | 2013-08-14 | 2016-09-15 | ラシオファルム ゲーエムベーハー | ドルテグラビル、エムトリシタビン及びテノホビルの医薬コンビネーションを有する医薬 |
| CN117088931A (zh) * | 2014-08-12 | 2023-11-21 | 莫纳什大学 | 定向淋巴的前药 |
| WO2016154527A1 (en) * | 2015-03-26 | 2016-09-29 | Merck Sharp & Dohme Corp. | Phosphate-substituted quinolizine derivatives useful as hiv integrase inhibitors |
| US10214516B2 (en) * | 2015-08-12 | 2019-02-26 | VIIV Healthcare UK (No.5) Limited | 5-(N-fused tricyclic aryl tetrahydroisoquinolin-6-yl) pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication |
| WO2017113288A1 (en) * | 2015-12-31 | 2017-07-06 | Merck Sharp & Dohme Corp. | Fused tricyclic heterocyclic compounds as hiv integrase inhibitors |
| US11117904B2 (en) | 2016-06-23 | 2021-09-14 | Viiv Healthcare Company | Compositions and methods for the delivery of therapeutics |
| CN119462611A (zh) * | 2016-08-19 | 2025-02-18 | 吉利德科学公司 | 用于预防性或治疗性治疗hiv病毒感染的治疗性化合物 |
| AR112412A1 (es) * | 2017-08-17 | 2019-10-23 | Gilead Sciences Inc | Formas de sal de colina de un inhibidor de la cápside del vih |
| EP3870174B1 (en) | 2018-10-22 | 2023-11-01 | Board of Regents of the University of Nebraska | Antiviral prodrugs and nanoformulations thereof |
| CN120535538A (zh) | 2018-11-29 | 2025-08-26 | 内布拉斯加大学董事会 | 抗病毒前药及其纳米制剂 |
| KR20230145313A (ko) | 2020-11-10 | 2023-10-17 | 유니티 바이오테크놀로지, 인크. | Bcl의 결정성 고체 메글루민 염 억제제 및 이의 제조 방법 및 이의 사용 방법 |
-
2019
- 2019-10-22 EP EP19877349.1A patent/EP3870174B1/en active Active
- 2019-10-22 MX MX2021004679A patent/MX2021004679A/es unknown
- 2019-10-22 IL IL320867A patent/IL320867A/en unknown
- 2019-10-22 ES ES23160610T patent/ES3062664T3/es active Active
- 2019-10-22 KR KR1020217015211A patent/KR102856407B1/ko active Active
- 2019-10-22 KR KR1020247026674A patent/KR102908976B1/ko active Active
- 2019-10-22 CA CA3117453A patent/CA3117453A1/en active Pending
- 2019-10-22 JP JP2021523014A patent/JP7437051B2/ja active Active
- 2019-10-22 SG SG11202104117WA patent/SG11202104117WA/en unknown
- 2019-10-22 IL IL282551A patent/IL282551B2/en unknown
- 2019-10-22 EA EA202190974A patent/EA202190974A1/ru unknown
- 2019-10-22 EP EP23160610.4A patent/EP4234561B1/en active Active
- 2019-10-22 CN CN202310352412.0A patent/CN116375735B/zh active Active
- 2019-10-22 BR BR112021007622-0A patent/BR112021007622A2/pt unknown
- 2019-10-22 ES ES19877349T patent/ES2970251T3/es active Active
- 2019-10-22 MY MYPI2021002213A patent/MY207622A/en unknown
- 2019-10-22 WO PCT/US2019/057406 patent/WO2020086555A1/en not_active Ceased
- 2019-10-22 CN CN201980085100.XA patent/CN113226319B/zh active Active
- 2019-10-22 AU AU2019368247A patent/AU2019368247B2/en active Active
- 2019-10-22 EP EP23160303.6A patent/EP4234560A3/en not_active Withdrawn
-
2021
- 2021-03-22 US US17/301,030 patent/US11154557B2/en active Active
- 2021-04-22 PH PH12021550905A patent/PH12021550905A1/en unknown
- 2021-04-22 MX MX2023012166A patent/MX2023012166A/es unknown
- 2021-04-22 SA SA521421845A patent/SA521421845B1/ar unknown
- 2021-04-28 ZA ZA2021/02846A patent/ZA202102846B/en unknown
- 2021-05-24 US US17/303,229 patent/US11311547B2/en active Active
- 2021-05-24 US US17/303,228 patent/US11166957B2/en active Active
-
2022
- 2022-03-18 US US17/655,483 patent/US12168013B2/en active Active
-
2024
- 2024-04-22 ZA ZA2024/03101A patent/ZA202403101B/en unknown
- 2024-08-22 AU AU2024213169A patent/AU2024213169A1/en active Pending
- 2024-12-09 US US18/973,233 patent/US20250099477A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022505928A5 (https=) | ||
| IL282551B1 (en) | Antiviral prodrugs and their nanoformulations | |
| JP2021100937A5 (https=) | ||
| JP2020097577A5 (https=) | ||
| JP2024516371A5 (https=) | ||
| JP2020505423A5 (https=) | ||
| RU2013121788A (ru) | Ингибиторы репликации вич | |
| JP2013507439A5 (https=) | ||
| JP2009536191A5 (https=) | ||
| IL273177B2 (en) | Fluorophenyl beta-hydroxyethylamines and their uses in the treatment of hyperglycemia | |
| JP2013509429A5 (https=) | ||
| JP2019529541A5 (https=) | ||
| JP2022525013A5 (https=) | ||
| RU2015149527A (ru) | Производные доластатина 10 и ауристатинов | |
| JP2011527299A5 (https=) | ||
| WO2009120697A4 (en) | Method and compositions for treatment of cancer | |
| JP2016510041A5 (https=) | ||
| SI2945620T1 (en) | Nitroxyl donors with improved therapeutic index | |
| JP2016503058A5 (https=) | ||
| CO2019004004A2 (es) | Composición farmacéutica y método para el tratamiento de la enfermedad del hígado graso no alcohólico | |
| JP2022531251A5 (https=) | ||
| JP2015512420A5 (https=) | ||
| JP2022551691A5 (https=) | ||
| JP2014148552A5 (https=) | ||
| JP2019513828A5 (https=) |